
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>ACG Clinical Guidelines: Management of Benign Anorectal Disorders</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>ACG Clinical Guidelines: Management of Benign Anorectal Disorders</strong></summary>
            <div>
                <ul><li>Info about the article:</li><li>Authors: Arnold Wald, Adil E. Bharucha, Berkeley Limketkai, Allison Malcolm, Jose M. Remes-Troche, William E. Whitehead, Massarat Zutshi</li><li>Journal: American Journal of Gastroenterology</li><li>Publication Date: 2021</li><li>DOI: https://doi.org/10.14309/ajg.0000000000001507</li><li>Focus: Evaluation and management of defecation disorders, proctalgia syndromes, hemorrhoids, anal fissures, and fecal incontinence in adults.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of healthy people might be misclassified as abnormal on a rectal balloon expulsion test using a Foley catheter inflated to 50 mL?</li><li>2. What is the recommended number of biofeedback therapy sessions for defecation disorders?</li><li>3. What is the reported range of improvement in preoperative constipation with ventral mesh rectopexy for rectal prolapse?</li><li>4. What percentage of patients with sigmoidoceles and enteroceles have recurrence of defecatory symptoms in the long term after sacrocolpopexy?</li><li>5. What is the reported range of healing rates for chronic anal fissures treated with lateral internal sphincterotomy (LIS)?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction</strong></summary>
            <div>
                <ul><li>Updated guidelines summarize definitions, diagnostic criteria, evaluation, and management of benign anorectal disorders.</li><li>Focus on disorders of defecation, proctalgia syndromes, fecal incontinence (functional disorders), anal fissures, and hemorrhoids (structural disorders).</li><li>Recommendations based on comprehensive search of relevant English language articles in PubMed, Ovid MEDLINE, and the National Library of Medicine updated to June 2020.</li></ul>
                
        <details>
            <summary><strong>Guideline Development</strong></summary>
            <div>
                <ul><li>Recommendations based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process.</li><li>Strong recommendation: benefits clearly outweigh negatives.</li><li>Conditional recommendation: uncertainty about balance of benefits and potential harms.</li><li>Key concepts: statements not amenable to GRADE process, based on extrapolation of evidence and/or expert opinion.</li></ul>
                
        <details>
            <summary><strong>Quality of Evidence (GRADE)</strong></summary>
            <div>
                <ul><li>High: Further research unlikely to change confidence in effect estimate.</li><li>Moderate: Moderate confidence; future studies likely to impact confidence.</li><li>Low: Further study likely to have important impact on confidence and change estimate.</li><li>Very-low: Very little confidence; true effect likely substantially different than estimate.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Consensus Agreement</strong></summary>
            <div>
                <ul><li>Each key concept and recommendation assessed by 6 authors on a five-point Likert scale.</li><li>Consensus agreement defined as a composite score of ≥ 25 (maximum of 30).</li><li>Guidelines support clinical practice and suggest preferable approaches based on available literature.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Defecation Disorders (DDs)</strong></summary>
            <div>
                <ul><li>Difficulty evacuating stool from rectum in patients w/ chronic/recurring constipation symptoms.</li><li>Diagnosis requires both constipation symptoms + anorectal tests suggesting impaired rectal evacuation.</li><li>Incidence more common in women than men; 3-fold more common than Crohn’s disease.</li></ul>
                
        <details>
            <summary><strong>Definition and Epidemiology</strong></summary>
            <div>
                <ul><li>DDs: Difficulty evacuating stool from rectum in patients w/ chronic/recurring constipation symptoms.</li><li>Diagnosis requires both constipation symptoms + anorectal tests suggesting impaired rectal evacuation.</li><li>Incidence more common in women than men; 3-fold more common than Crohn’s disease.</li></ul>
                
        <details>
            <summary><strong>Incidence by Gender and Age</strong></summary>
            <div>
                <ul><li>Women: Greatest incidence between 20–29 years, second peak between 80–89 years.</li><li>Men: Incidence increases w/ age until 80–89 years.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>Maladaptive learning of sphincter contraction underlies DD.</li><li>Evacuation impaired ∵ inadequate rectal propulsive forces and/or ↑ outlet resistance.</li><li>Other abnormalities: ↓ rectal sensation, structural deformities (rectoceles, excessive perineal descent).</li></ul>
                
        <details>
            <summary><strong>Impaired Evacuation</strong></summary>
            <div>
                <ul><li>Inadequate rectal propulsive forces and/or increased outlet resistance.</li><li>Impaired relaxation or paradoxical contraction of external anal sphincter and/or puborectalis muscle.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Associated Abnormalities</strong></summary>
            <div>
                <ul><li>Reduced rectal sensation may reduce desire to defecate.</li><li>Up to 50% of patients w/ DD also have delayed colonic transit.</li><li>Excessive straining can weaken pelvic floor → excessive perineal descent, rectal intussusception, solitary rectal ulcer syndrome, pudendal neuropathy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Uncertainties</strong></summary>
            <div>
                <ul><li>Extent to which dyssynergia is responsible for impaired evacuation is uncertain.</li><li>Relative contribution of structural abnormalities (e.g., large rectocele) to symptoms is unclear.</li><li>Stool form may influence expression of pelvic floor dysfunction; strain more to evacuate hard stools.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Associated Conditions</strong></summary>
            <div>
                <ul><li>DDs often begin in childhood; many patients have IBS, anxiety, and/or depression.</li><li>Other associated conditions/risk factors: surgery, hospitalization, eating disorders, trauma, physical/sexual abuse.</li><li>Obstetric trauma is NOT associated w/ DD.</li></ul>
                
        <details>
            <summary><strong>Secondary Causes</strong></summary>
            <div>
                <ul><li>Parkinson disease.</li><li>Inflammatory bowel disease before or after ileal pouch–anal anastomosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Features</strong></summary>
            <div>
                <ul><li>Symptoms: infrequent defecation, hard stools, excessive straining, sense of anorectal blockage, use of manual maneuvers, sense of incomplete evacuation.</li><li>Symptoms do not discriminate between DD and other causes of constipation.</li><li>Digital Rectal Examination (DRE) can identify structural abnormalities and assess anal sphincter functions.</li></ul>
                
        <details>
            <summary><strong>Digital Rectal Examination (DRE)</strong></summary>
            <div>
                <ul><li>DRE includes perianal inspection + digital assessment to assess stool in rectum, anal tone at rest, during voluntary contraction (squeeze) and simulated evacuation.</li><li>During simulated evacuation, anal sphincter should relax.</li><li>Failure to relax may suggest DD or reflect challenges of simulating evacuation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>DRE Findings</strong></summary>
            <div>
                <ul><li>Palpate puborectalis muscle; normal response is for muscle to relax, widening anorectal angle.</li><li>Assessments of anal tone at rest, during squeeze and evacuation, and perineal descent during evacuation w/ meticulous DRE are significantly correlated w/ objective assessments.</li><li>Compared w/ manometry, DRE was 75% sensitive and 87% specific for identifying dyssynergia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>DRE vs. Balloon Expulsion Test (BET)</strong></summary>
            <div>
                <ul><li>Compared w/ rectal BET, sensitivity and specificity were 80% and 56%, respectively.</li><li>Normal DRE probably more useful than abnormal result.</li><li>All patients w/ constipation w/ symptoms refractory to standard therapy should be referred for anorectal testing to exclude DD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Tests</strong></summary>
            <div>
                <ul><li>Anorectal tests are necessary ∵ symptoms alone do not discriminate between DD and other causes of constipation.</li><li>Tests assess rectal sensation and anorectal pressures (manometry), rectal balloon expulsion (BET), external anal sphincter and pelvic floor muscle activity (EMG), or rectal evacuation (barium or MRI defecography).</li><li>All tests have strengths and limitations; no single gold standard.</li></ul>
                
        <details>
            <summary><strong>Test Selection</strong></summary>
            <div>
                <ul><li>ARM and BET are performed in conjunction, followed by defecography if discrepancy between clinical features and initial tests, and/or discrepancy between manometry and BET, and/or in patients w/ clinically suspected pelvic organ prolapse.</li><li>Test results should be interpreted together w/ clinical features ∵ false-positive and false-negative results are not uncommon.</li><li>Rome IV criteria: diagnosis of DD be confirmed by at least 2 abnormal tests.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Test Concordance</strong></summary>
            <div>
                <ul><li>Results of anorectal high-resolution anorectal manometry (HRM), BET, and MRI defecography are concordant w/ levels of agreement &gt;70%.</li><li>Different tests may not agree in individual patients.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Rectal Balloon Expulsion Test (BET)</strong></summary>
            <div>
                <ul><li>Measures time required to evacuate a balloon filled w/ 50 mL of warm water in seated position.</li><li>Using a party or commercial balloon, upper limit of normal is 1 minute.</li><li>When using a Foley catheter inflated to 50 mL, upper limit of normal is 2 minutes.</li></ul>
                
        <details>
            <summary><strong>Foley Catheter Caution</strong></summary>
            <div>
                <ul><li>Even w/ 2-minute cutoff, 25% of healthy people would be misclassified as abnormal using a Foley catheter.</li><li>Discourage use of Foley catheter balloons in favor of commercially available ones or locally constructed ones based on centers that have reported normative data.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BET Sensitivity and Specificity</strong></summary>
            <div>
                <ul><li>In a series of 106 patients w/ functional constipation and 24 patients w/ DD, BET identified those w/ DD, as documented w/ defecography, w/ sensitivity and specificity of ≈ 88%.</li><li>Positive and negative predictive values were 64% and 97%, respectively, for diagnosis of DD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Anorectal Manometry</strong></summary>
            <div>
                <ul><li>Measures rectal sensation and anorectal pressures at rest, during anal and pelvic floor contraction (squeeze), evacuation, and a cough or Valsalva maneuver.</li><li>Conventional catheters: water-perfused, air-charged, or solid-state sensors.</li><li>High-resolution manometry (HRM): more closely spaced sensors, better spatial resolution.</li></ul>
                
        <details>
            <summary><strong>HRM vs. Conventional Catheters</strong></summary>
            <div>
                <ul><li>Measurements w/ conventional and HRM catheters are comparable.</li><li>Values are greater w/ HRM than w/ conventional catheters; pressures must be compared w/ reference values measured w/ same technique.</li><li>Reference values characterized in relatively few individuals, more so in women than in men.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Evacuation Studies</strong></summary>
            <div>
                <ul><li>Summarized by rectal and anal pressures, anal relaxation, and rectoanal gradient.</li><li>Normal evacuation requires a positive rectoanal gradient (rectal pressure &gt; anal pressure).</li><li>Many healthy people exhibit a negative rectoanal gradient.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Paradoxical Anal Contraction</strong></summary>
            <div>
                <ul><li>37% of asymptomatic women fail to relax or paradoxically contract their pelvic floor muscles during evacuation.</li><li>Seated manometry may be more useful than left lateral manometry for discriminating between healthy people and patients w/ DD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Barium and Magnetic Resonance Defecography</strong></summary>
            <div>
                <ul><li>Performed by injecting barium contrast mixed w/ psyllium or another thickening agent into rectum (barium defecography) or gel (magnetic resonance [MR] defecography) and taking lateral images of anorectum at rest, during pelvic floor contraction, and defecation.</li><li>Angle between axes of rectum and anal canal provides indirect measure of whether puborectalis muscle relaxes (normal response) or contracts (indicative of DD) during simulated defecation.</li></ul>
                
        <details>
            <summary><strong>Abnormalities Identified</strong></summary>
            <div>
                <ul><li>Inadequate or excessive widening of anorectal angle and/or perineal descent during defecation.</li><li>Internal intussusception, solitary rectal ulcers, rectoceles, and rectal prolapse may also be identified.</li><li>Enteroceles, bladder, and uterovaginal prolapse can be visualized when vagina and small intestine are opacified.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations of Barium Defecography</strong></summary>
            <div>
                <ul><li>Limited reproducibility of anorectal angle measurements, which can be overcome w/ standardized techniques.</li><li>MR defecography is performed in supine position; barium defecography is performed in seated position.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Advantages of MR Defecography</strong></summary>
            <div>
                <ul><li>Avoids radiation exposure, provides more precise assessments of pelvic organ prolapse and pelvic floor motion.</li><li>Useful for uncovering pelvic floor dysfunction in patients who have clinical features of DD w/ normal BET; includes &gt;90% of patients w/ large rectocele, enterocele, and/or peritoneocele.</li><li>Less widely available and more expensive.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Anal EMG</strong></summary>
            <div>
                <ul><li>Average anal EMG activity recorded by electrodes mounted on an acrylic anal plug or taped to perianal skin.</li><li>May be used to identify dyssynergia and to provide biofeedback training for DD.</li><li>Reduction of ≥20% in anal EMG activity during evacuation is considered normal.</li></ul>
                
        <details>
            <summary><strong>EMG Correlation</strong></summary>
            <div>
                <ul><li>&lt;20% reduction during evacuation correlated w/ dyssynergic defecation, as identified by manometry and abnormal BET.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Colon Transit</strong></summary>
            <div>
                <ul><li>Colonic transit should only be evaluated in patients who do not respond after biofeedback therapy or who exhibit normal anorectal function during testing.</li><li>Can be performed w/ radiopaque markers, colon scintigraphy, or wireless motility capsule after discontinuing medications that can affect colonic transit.</li></ul>
                
        <details>
            <summary><strong>Radio-opaque Marker Studies</strong></summary>
            <div>
                <ul><li>Inexpensive, easily available, easy to perform, and entail modest radiation exposure.</li><li>Up to 50% of patients w/ DD exhibit slow colonic transit if tested; such patients should be treated initially w/ pelvic biofeedback therapy ∵ slow transit often normalizes w/ successful biofeedback.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Scintigraphy or Wireless Capsule</strong></summary>
            <div>
                <ul><li>May be used when it is also desirable to measure gastric emptying and small intestinal transit.</li><li>If patients can only discontinue medications for a few days, scintigraphy is preferred.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Differential Diagnosis</strong></summary>
            <div>
                <ul><li>DDs may be associated w/ IBS and conditions associated w/ rectal bleeding (e.g., hemorrhoids or solitary rectal ulcer).</li><li>Abdominal imaging and/or colonoscopy should be considered when clinically indicated.</li><li>Some patients w/ severe symptoms have anxiety, depression, or generalized somatoform disorders that need to be addressed concurrently.</li></ul>
                
        <details>
            <summary><strong>DD and Structural Abnormalities</strong></summary>
            <div>
                <ul><li>In patients w/ DD and excessive perineal descent, w/ or w/o pelvic organs prolapse, it can be challenging to determine contributions of structural and functional disturbances to DD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Slow Transit Constipation</strong></summary>
            <div>
                <ul><li>May occur in isolation or coexist w/ DD.</li><li>In up to two-thirds of patients w/ the latter, slow colonic transit is probably secondary to outlet dysfunction rather than an independent, comorbid condition.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>Anorectal biofeedback therapy is the cornerstone for managing DD.</li><li>Other conservative measures are also helpful, especially ∵ anorectal biofeedback therapy is not widely available or may not benefit all patients.</li><li>Potential options: eliminate medications that cause constipation, use of soluble fiber or laxatives for hard stools, insoluble fiber for loose stools, or regular toileting.</li></ul>
                
        <details>
            <summary><strong>Conservative Treatment Details</strong></summary>
            <div>
                <ul><li>Consideration should be given for use of a footstool to enhance defecation.</li><li>Advise patients to consume meals of ≥500 Kcal to induce gastrocolonic response, heed call to defecate, and avoid straining and spending excessive time during defecation.</li><li>Anorectal conditions (e.g., anal fissure or symptomatic hemorrhoids) should be treated concurrently.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laxatives and Enemas</strong></summary>
            <div>
                <ul><li>If conservative measures are insufficient, oral osmotic or stimulant laxatives, secretory agents, or serotonin 5HT4 agonists may be considered.</li><li>Administered on an as-needed basis (e.g., if patients do not have a bowel movement for 2 days), enemas and suppositories provide some predictability over bowel habits.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pelvic Floor Therapy</strong></summary>
            <div>
                <ul><li>Pelvic floor therapy does not provide feedback from pelvic floor muscles, is not specific for disorders of defecation, and is not effective for managing DD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Anorectal Biofeedback Therapy</strong></summary>
            <div>
                <ul><li>Aim is to improve symptoms by teaching patients to appropriately coordinate abdominal and pelvic floor muscles during defecation.</li><li>Through 1 or more techniques (ARM, abdominal and anal EMG, assessment of rectal sensation, and ability to expel a rectal balloon), patients receive visual and verbal feedback of their anorectal disturbances and are taught corrective approaches.</li></ul>
                
        <details>
            <summary><strong>Biofeedback Components</strong></summary>
            <div>
                <ul><li>Teaching abdominal breathing and a method to generate adequate propulsive force during defecation.</li><li>Teaching patients to relax anal sphincter and synchronize this w/ ↑ rectal pressure.</li><li>Rectal sensory retraining to enhance rectal perception in patients w/ hyposensitivity.</li><li>Balloon expulsion retraining to shorten time to balloon expulsion.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biofeedback Sessions</strong></summary>
            <div>
                <ul><li>Four to 6 sessions, each several weeks apart, are recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biofeedback Efficacy</strong></summary>
            <div>
                <ul><li>Several randomized controlled trials (RCTs) suggest that anorectal biofeedback therapy improves symptoms in DD.</li><li>Comparators have included diet, exercise, and laxatives, polyethylene glycol, diazepam, or placebo, balloon defecation training, and sham biofeedback therapy.</li><li>Most studies show efficacy for short-term outcomes, although evidence for longer-term efficacy is of low quality.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biofeedback Safety and Availability</strong></summary>
            <div>
                <ul><li>Anorectal biofeedback therapy is very safe but is labor intensive, involves considerable specialized expertise, and is not widely available.</li><li>Baseline ARM and balloon expulsion and a history suggestive of abnormal toileting behavior such as digitation may possibly predict response to biofeedback; further studies required.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Surgery and Minimally Invasive Procedures</strong></summary>
            <div>
                <ul><li>Conservative measures and biofeedback therapy for defecatory disorders may not always provide adequate relief of symptoms.</li><li>In such patients, it may be appropriate to perform investigations such as MR or barium defecography to look for structural disorders to explain symptoms.</li><li>Structural abnormalities of pelvic floor occur commonly in asymptomatic subjects and usually do not require surgical correction.</li></ul>
                
        <details>
            <summary><strong>Surgical Exceptions</strong></summary>
            <div>
                <ul><li>Overt rectal prolapse.</li><li>Sizeable, nonemptying rectocele when defecatory symptoms are associated w/ typical symptoms of vaginal bulge or prolapse.</li><li>Utility of repairing enteroceles or sigmoidoceles is unclear.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Rectal Prolapse</strong></summary>
            <div>
                <ul><li>Patients who present w/ overt full-thickness rectal prolapse, w/ or w/o defecatory symptoms and/or progressive FI, should be considered for surgical correction.</li><li>If prolapse is suspected, but not demonstrated on rectal examination in left lateral position, examination should be repeated w/ patient squatting or sitting on a toilet or commode.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laparoscopic Rectopexy</strong></summary>
            <div>
                <ul><li>For most patients w/ full-thickness prolapse, laparoscopic rectopexy (either posterior or ventral) is most appropriate operation as it is associated w/ a substantially lower recurrence rate than perineal procedures such as Altemeier procedure (27% recurrence rate).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Perineal Procedures</strong></summary>
            <div>
                <ul><li>Perineal procedures such as Altemeier or Delorme procedure are a reasonable option for patients who are elderly or frail.</li><li>Effect of these procedures on constipation is variable but is best substantiated w/ ventral mesh rectopexy, which leads to 66%–86% improvement in preoperative constipation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cautionary Groups for Surgery</strong></summary>
            <div>
                <ul><li>Psychiatric disorders, chronic pain or IBS, morbid obesity, joint hypermobility, connective tissue disorders, women planning pregnancy or those at high risk for pelvic surgery due to previous surgery, infection, or radiotherapy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Rectocele Surgery Considerations</strong></summary>
            <div>
                <ul><li>Rectoceles are often identified on clinical examination or defecography in asymptomatic women and usually do not require surgery.</li><li>Rectocele surgery should be considered for patients w/ bothersome gynecological symptoms such as bulging in perineum or protrusion through vaginal introitus.</li></ul>
                
        <details>
            <summary><strong>Conservative Management First</strong></summary>
            <div>
                <ul><li>In absence of gynecological symptoms, women who present w/ defecatory dysfunction and a coexistent rectocele should be initially managed conservatively, including biofeedback therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Features Suggesting Surgery</strong></summary>
            <div>
                <ul><li>Significant size of rectocele based on clinical assessment and/or imaging (e.g., &gt;5 cm).</li><li>Evidence of trapping or nonemptying on dynamic assessment such as defecography.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Transvaginal Repairs</strong></summary>
            <div>
                <ul><li>Transvaginal repairs using native tissue are preferred, and use of a vaginal mesh repair has been discontinued by US Food and Drug Administration.</li><li>Short-term success rates for surgery reported to be in order of 73%; however, most studies lack uniform validated outcome measures.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Stapled Transanal Rectal Resection (STARR)</strong></summary>
            <div>
                <ul><li>Alternative approach to rectovaginal reinforcement surgery for rectocele that is predominantly performed in Europe (Italy).</li><li>Small RCTs, a large observational study, and a systematic review have shown efficacy for treating constipation, but others have expressed concerns about these reports and outcomes of this procedure.</li></ul>
                
        <details>
            <summary><strong>Concerns About STARR</strong></summary>
            <div>
                <ul><li>Insufficient characterization of defecatory disorder at baseline, as BET was not performed and anal pressures were not reported.</li><li>Quality of biofeedback performed as a comparator was inadequate according to current guidelines.</li><li>Newer versions of stapling device might ameliorate concerns about reported complications.</li><li>Currently, procedure is not widely performed in other countries.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Sigmoidocele and Enterocele</strong></summary>
            <div>
                <ul><li>Components of pelvic organ prolapse that often include uterine/vaginal vault prolapse, cystoceles, and rectoceles.</li><li>When thought to be symptomatic, enteroceles and sigmoidoceles may be treated w/ surgical repair (e.g., sacrocolpopexy) after careful radiological testing using MRI, defecating proctogram, and/or transperineal ultrasound.</li></ul>
                
        <details>
            <summary><strong>Sacrocolpopexy Outcomes</strong></summary>
            <div>
                <ul><li>Seems to result in acceptable reduction of anatomical defect but has a very high recurrence of defecatory symptoms (75% of patients in long term [85 months]) and 23% have recurrent pelvic discomfort.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Surgical Approaches (No Structural Abnormality)</strong></summary>
            <div>
                <ul><li>In patients who have failed medical management and biofeedback and have proven dyssynergia due to dysfunction of puborectalis muscle, injections of botulinum toxin A into anal sphincter complex have been used.</li><li>Botulinum toxin A has a reversible paralytic effect on nerve endings of muscles w/ growth of new nerve fibrils in 2–3 months.</li></ul>
                
        <details>
            <summary><strong>Botulinum Toxin A Review</strong></summary>
            <div>
                <ul><li>Recent systematic review of botulinum toxin A was based on 3 small RCTs and 8 small uncontrolled studies.</li><li>Study design, techniques for administering botulinum toxin, and outcome assessments varied considerably between studies.</li><li>Authors concluded that “the evidence to support using BTX for DD is poor.”</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Botulinum Toxin A Adverse Effects</strong></summary>
            <div>
                <ul><li>Combined adverse effects in this review were 14.2% and included flatus and FI and occasionally, more serious side effects.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Sacral Nerve Stimulation (SNS)</strong></summary>
            <div>
                <ul><li>Involves peripheral nerve stimulation of S3 or S4 nerve roots in sacral foramina and is most often used to treat FI.</li><li>Three RCTs have shown no benefit of SNS in constipation (regardless of type).</li><li>Long-term complication rate is considerable, w/ 61% reporting device-related adverse events in a long-term (60 months) follow-up study.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Proctalgia Syndromes</strong></summary>
            <div>
                <ul><li>History of recurrent episodes of anorectal pain in absence of other known causes of pain based on history and diagnostic testing.</li><li>Divided into chronic and acute syndromes based on duration of painful episodes.</li><li>Chronic proctalgia syndrome: recurring episodes of anorectal pain lasting ≥20 minutes.</li></ul>
                
        <details>
            <summary><strong>Chronic Proctalgia</strong></summary>
            <div>
                <ul><li>Most common theory: excessive tension of pelvic floor muscles, specifically puborectalis or levator ani muscles.</li><li>Reinforced by demonstration of tenderness of levator ani muscle on DRE.</li><li>In absence of such finding, term chronic idiopathic proctalgia syndrome should be used.</li></ul>
                
        <details>
            <summary><strong>Overlap of Symptoms</strong></summary>
            <div>
                <ul><li>Often overlap of symptoms between chronic proctalgia and other conditions centered in pelvic area such as chronic prostatitis in men and chronic pelvic pain syndrome in women.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>ARM and Balloon Expulsion Testing</strong></summary>
            <div>
                <ul><li>Advocated performing ARM and balloon expulsion testing in patients w/ levator syndrome but not idiopathic chronic proctalgia syndrome to identify patients who might benefit from biofeedback therapy.</li><li>Failure to evacuate a 50 mL water filled balloon and manometric demonstration of inability to relax pelvic floor muscles during simulated defecation in patients w/ levator tenderness were often improved w/ biofeedback.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment Recommendations</strong></summary>
            <div>
                <ul><li>Biofeedback has no significant risks, and there are no effective alternative therapies.</li><li>Recommendation for electrogalvanic stimulation, which was less effective than biofeedback but was superior to conservative treatment.</li><li>No evidence to support use of botulinum toxin or digital rectal massage to treat either levator syndrome or chronic idiopathic proctalgia syndrome.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Proctalgia Fugax (PF)</strong></summary>
            <div>
                <ul><li>Intense sensations of rectal or anal pain lasting only a few seconds to &lt;20 minutes.</li><li>Diagnosis based on characteristic history and normal DRE.</li><li>Presence of anorectal conditions such as prolapsed hemorrhoids, chronic anal fissure, or other conditions does not invalidate diagnosis of PF.</li></ul>
                
        <details>
            <summary><strong>Pathophysiology and Triggers</strong></summary>
            <div>
                <ul><li>Pathophysiology remains unknown, and no trigger events are consistently identified.</li><li>Rare congenital form of this disorder has been identified as have patients w/ thickening of internal anal sphincter associated w/ elevated resting pressure.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment Approach</strong></summary>
            <div>
                <ul><li>Explanation of disorder and reassurance.</li><li>Given brevity of episodes of PF, there is no evidence to support treatment intervention or to prevent attacks.</li><li>Do not endorse treatment of any kind.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Anal Fissures</strong></summary>
            <div>
                <ul><li>Ulcer-like longitudinal tear in midline of anal canal, distal to dentate line.</li><li>In ≈90% of cases, idiopathic fissure is located in posterior midline, but can also occur in anterior midline.</li><li>Fissures in lateral positions should raise suspicion for disease processes.</li></ul>
                
        <details>
            <summary><strong>Lateral Fissure Suspicion</strong></summary>
            <div>
                <ul><li>Crohn’s disease, tuberculosis, syphilis, human immunodeficiency virus/acquired immunodeficiency syndrome, dermatologic conditions (e.g., psoriasis), and anal carcinoma.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>Often, history of tearing sensation during passage of hard stool or diarrhea.</li><li>Rectal bleeding is frequent and occurs during or after defecation and is usually limited to minimal bright red blood on toilet tissue.</li><li>Chronicity results in nonhealing ulcer due to spasm of internal anal sphincter muscle and consequent ischemia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Features</strong></summary>
            <div>
                <ul><li>Acute anal fissure: simple tear in endoderm.</li><li>Chronic fissure: nonhealing anal fissure lasting &gt;8–12 weeks; characterized by overhanging edges, edema, and fibrosis w/ fibers of internal anal sphincter visible in floor of fissure.</li><li>Typical accompanying features: sentinel pile (skin tag) at distal fissure margin and hypertrophied anal papilla in anal canal proximal to fissure.</li></ul>
                
        <details>
            <summary><strong>Clinical Hallmark</strong></summary>
            <div>
                <ul><li>Pain during defecation and often persisting after defecation.</li><li>Rectal bleeding is frequent and occurs during or after defecation and is usually limited to minimal bright red blood on toilet tissue.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Medical Management</strong></summary>
            <div>
                <ul><li>Almost half of all patients w/ acute anal fissure will heal w/ sitz baths and fiber supplements such a psyllium as first step in therapy, w/ or w/o addition of topical anesthetics or anti-inflammatory ointments.</li><li>Symptomatic relief of pain and bleeding can be achieved w/ virtually no side effects.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Chronic Anal Fissure Treatment</strong></summary>
            <div>
                <ul><li>Often treated w/ topical pharmacologic agents such as calcium channel blockers or nitrates.</li><li>Treatment w/ topical nitrates is marginally superior to placebo in healing of a chronic anal fissure w/ a short-term decrease in anal pressures.</li></ul>
                
        <details>
            <summary><strong>Topical Nitrates</strong></summary>
            <div>
                <ul><li>In a study using 3 doses of topical nitroglycerine vs placebo, 0.1%, 0.2%, and 0.4% nitroglycerin ointments were applied twice daily for 8 weeks.</li><li>Healing reported in 50%, 36%, and 57% of patients, respectively, compared w/ 26% in placebo group.</li><li>Most common side effect was headache, which was dose related.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cochrane Review</strong></summary>
            <div>
                <ul><li>Topical nitroglycerin remains only marginally better 48.9% vs 35.5% than placebo in healing chronic anal fissures.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Topical Calcium Channel Blockers</strong></summary>
            <div>
                <ul><li>Few studies reporting calcium channel blockers and none reporting a dose escalation.</li><li>Healing rate reported w/ a topical calcium channel blocker ≈ 67% to 90%, w/ long-term healing reported in 70% of patients; side effects consisted mainly of headache in 20%, and ≈10% of patients stopped treatment due to this side effect in an uncontrolled study.</li></ul>
                
        <details>
            <summary><strong>Topical Diltiazem</strong></summary>
            <div>
                <ul><li>One study reported a healing rate of 91.7% w/ topical diltiazem (2%) vs 60% w/ topical nitroglycerine (0.2%).</li><li>Incidence of headache was lower w/ topical diltiazem (0%) than w/ nitroglycerine (100%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Nifedipine vs. Nitroglycerine</strong></summary>
            <div>
                <ul><li>One compared nifedipine w/ topical nitrate medications.</li><li>Showed a healing rate of 80% w/ nifedipine, 73% w/ 0.2% nitroglycerine, and 33% w/ placebo, w/ recurrence rates of 12%, 32%, and 50% w/ nifedipine, nitroglycerine, and placebo, respectively.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Overall Calcium Channel Blocker Efficacy</strong></summary>
            <div>
                <ul><li>Insufficient data to conclude whether calcium channel blockers are superior to placebo in healing anal fissures.</li><li>Side effects such as headache occur less frequently than w/ topical nitrates.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Oral vs. Topical Calcium Channel Blockers</strong></summary>
            <div>
                <ul><li>Oral calcium channel blockers may be as efficacious as topical calcium channel blockers, suggesting that it is the drug rather than the route of administration that is important; healing rates were 90% for topical vs 76% for oral.</li><li>Side effects included headache most frequently and ankle edema and were not significantly increased w/ oral route.</li></ul>
                
        <details>
            <summary><strong>Nifedipine Formulations</strong></summary>
            <div>
                <ul><li>One small study of 27 patients tested nifedipine 0.5% and reported 85% healing w/ a recurrence rate of 16% and a 7.4% occurrence of moderate headaches; another study reported 83% healing and better compliance when compared w/ nitroglycerine.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Topical Diltiazem Preference</strong></summary>
            <div>
                <ul><li>Topical diltiazem 2% had a lower incidence of adverse effects than did topical nitroglycerin and was preferred to nitroglycerin.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Minimally Invasive Procedures</strong></summary>
            <div>
                <ul><li>Botulinum toxin A injection for chronic anal fissures in doses of 5–100 units has been reported to have superior healing rates compared w/ placebo, although w/ disadvantage of requiring a needle injection in a sensitive area.</li><li>No consensus on dosage, precise site of administration, number of injections, or efficacy.</li></ul>
                
        <details>
            <summary><strong>Botulinum Toxin A Healing Rates</strong></summary>
            <div>
                <ul><li>In 1 study, injection of botulinum toxin into internal anal sphincter reported healing in 60%–80% of fissures and at a higher rate than placebo.</li><li>Most common side effect is temporary incontinence of flatus in up to 18% and of stool in 5%.</li><li>Recurrence may occur in up to 42%, but patients may be retreated w/ similar results to initial treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cochrane Review on Botulinum Toxin A</strong></summary>
            <div>
                <ul><li>Botulinum toxin A has only marginal improvement over placebo.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Topical Nitrate Potentiation</strong></summary>
            <div>
                <ul><li>Topical nitrate medications may potentiate effects of botulinum toxin in patients w/ refractory anal fissure.</li><li>Predictors of efficacy may include female sex, satisfaction w/ first procedure, and a lower body mass index.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Surgical Interventions</strong></summary>
            <div>
                <ul><li>Lateral Internal Sphincterotomy (LIS): procedure that involves cutting fibers of internal anal sphincter muscle up to apex of fissure or dentate line; may be performed under general, spinal, or local anesthesia.</li><li>Remains surgical treatment of choice for chronic anal fissures that are refractory to medical treatment.</li></ul>
                
        <details>
            <summary><strong>LIS Healing Rates</strong></summary>
            <div>
                <ul><li>Healing rates have been reported between 94% and 98% and are clearly superior to uncontrolled manual anal dilation, w/ better healing rates and less incontinence.</li><li>Also more efficacious than any topical or injectable treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>LIS Technique</strong></summary>
            <div>
                <ul><li>No outcome difference between open and closed sphincterotomy, and thus, a minimal-incision approach is probably preferred.</li><li>Low but real incidence of FI from LIS, and hence, surgeons continue to explore alternative interventions.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pneumatic Balloon Dilation</strong></summary>
            <div>
                <ul><li>Controlled pneumatic balloon dilation has shown promise as an alternative to LIS in 1 small series.</li><li>Surgical referral remains prudent for most cases of medical treatment failure in chronic anal fissure ∵ LIS is a safe and effective operation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>LIS Caution</strong></summary>
            <div>
                <ul><li>LIS should be used w/ caution in patients when anal pressures are not high, but these determinations are usually made by digital examination only.</li><li>In such cases, anal advancement flap repair or a V-Y plasty would be recommended.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Anal Fissures and Crohn&#x27;s Disease</strong></summary>
            <div>
                <ul><li>In patients w/ Crohn’s disease, medical management is recommended, and LIS should be used w/ great caution.</li><li>Refractory chronic anal fissures should be treated first w/ calcium channel blocker; role of botulinum toxin A is uncertain.</li><li>LIS may be considered in patients w/ rectal sparing disease w/ good resting and squeeze pressures.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hemorrhoids</strong></summary>
            <div>
                <ul><li>Vascular tissue covered w/ anal mucosa normally present in anal canal and is termed anal cushions and is an integral part of mechanism for anal sensation and preservation of continence.</li><li>Anal cushions are termed internal hemorrhoids when they bleed or enlarge and protrude into anal canal from above dentate line.</li></ul>
                
        <details>
            <summary><strong>Internal Hemorrhoid Grading</strong></summary>
            <div>
                <ul><li>Grade 1: not associated w/ prolapse.</li><li>Grade 2: prolapse w/ straining and spontaneously reduce after bowel movement.</li><li>Grade 3: prolapse and need manual reduction.</li><li>Grade 4: prolapse and are not manually reducible.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>External Hemorrhoids</strong></summary>
            <div>
                <ul><li>Located distal to dentate line and are covered by squamous epithelium.</li><li>Painful only when they develop an acute thrombosis but are otherwise painless.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>Internal hemorrhoids thought to occur ∵ loss of connective tissue support and prolapse making them more susceptible to trauma from straining and/or passage of hard stools.</li><li>Constipation and sitting on toilet for long periods of time thought to predispose to their development and symptoms.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Features</strong></summary>
            <div>
                <ul><li>Cardinal signs of internal hemorrhoids: hemorrhoid-pattern bleeding—defined as painless bleeding w/ bowel movements—and intermittent, reducible protrusion.</li><li>Role of gastroenterologist to provide diagnosis of exclusion of symptomatic internal hemorrhoids by ruling out other sources of bleeding and protrusion.</li><li>External hemorrhoids present w/ painful swelling.</li></ul>
                
        <details>
            <summary><strong>Anal Skin Tags</strong></summary>
            <div>
                <ul><li>Represent residual redundant skin from previous episodes of inflammation and thrombosis and are painless.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Medical Management</strong></summary>
            <div>
                <ul><li>Symptomatic internal hemorrhoids may be treated w/ conservative management that include bowel management w/ advice on increasing fluid (6–8 glasses of fluids daily) and dietary fiber intake (20–30 g daily), discouraging sitting on toilet for a prolonged time, which includes reading and use of cell phone.</li><li>For patients unable to increase their dietary fiber, polyethylene glycol 3,350 or docusate may be given.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conservative Management Evidence</strong></summary>
            <div>
                <ul><li>Evidence for conservative management is moderate, but recommendation is strong based on correction of presumed pathogenesis and minimal risk of complications when compared w/ office procedures.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Office-Based Procedures</strong></summary>
            <div>
                <ul><li>Symptomatic first- and second-degree hemorrhoids not responding to conservative management may be treated in office w/ rubber band ligation.</li><li>Rubber band ligation (banding) is most popular and effective office treatment for internal hemorrhoids.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Rubber Band Ligation</strong></summary>
            <div>
                <ul><li>Evidence is low due to paucity of data on Grade 1 hemorrhoids; however, recommendation is strong as procedure is relatively simple, complications are low, and it may be easily repeated if symptoms recur.</li><li>Ligation of hemorrhoids can be accomplished through a rigid anoscope or using a retroflexed flexible endoscope w/ a ligation attachment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Banding Meta-Analysis</strong></summary>
            <div>
                <ul><li>In a meta-analysis of 18 randomized prospective studies of office treatments, banding had a lower need for repeated treatment, compared w/ injection sclerotherapy and infrared coagulation, in treatment of first- to third-degree hemorrhoids.</li><li>Most common complications of banding are anorectal pain, bleeding, thrombosis of external hemorrhoids, and vasovagal symptoms that occur in 1%–3% of patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Other Treatment Options</strong></summary>
            <div>
                <ul><li>Infrared coagulation, sclerotherapy, or bipolar coagulation.</li><li>Sclerotherapy is successful in treating 75%–90% of patients w/ first- to third-degree hemorrhoids.</li><li>Recurrence is frequent, but retreatment is considered safe, w/ complications similar to ligation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Infrared Coagulation</strong></summary>
            <div>
                <ul><li>Involves contact application of infrared heat via a device inserted under vision through an anoscope, essentially cauterizing around base of hemorrhoid.</li><li>Most commonly used for first- and second-degree hemorrhoids.</li><li>Randomized trials have demonstrated outcomes similar to banding.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Grade 3 Hemorrhoid Treatment</strong></summary>
            <div>
                <ul><li>Symptomatic grade 3 hemorrhoids may be treated w/ Doppler-guided hemorrhoidal ligation w/ a hemorrhoidopexy, mucopexy, or a stapled hemorrhoidectomy.</li><li>Recommendation for Doppler-guided hemorrhoidal ligation is moderate, although quality of evidence is low, as it is relatively non-invasive.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Doppler-Assisted Hemorrhoidal Artery Ligation</strong></summary>
            <div>
                <ul><li>Uses a Doppler-equipped anoscope to identify and ligate arteries supplying internal hemorrhoids.</li><li>Followed by a hemorrhoidopexy or a rectoanal repair.</li><li>Potential benefit is that no tissue is excised.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Stapled Hemorrhoidectomy</strong></summary>
            <div>
                <ul><li>Has been shown to have higher complication and long-term recurrence rates; it has been less frequently used as a treatment alternative in recent years.</li><li>When compared w/ office procedures, traditional hemorrhoidectomy was more effective for grade III hemorrhoids, but more painful, and had a higher complication rate in 1 study.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Grade 4 Hemorrhoid Treatment</strong></summary>
            <div>
                <ul><li>Traditional hemorrhoidectomy remains recommended treatment for Grade 4 hemorrhoids.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Thrombosed External Hemorrhoids</strong></summary>
            <div>
                <ul><li>Present w/ sudden onset of pain and swelling that may be external to anal verge or just inside anal verge.</li><li>May be treated surgically if seen within 4 days.</li><li>Procedure is excision of clot w/ removal of overlying skin to prevent recurrence.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conservative Treatment for Thrombosed Hemorrhoids</strong></summary>
            <div>
                <ul><li>Involves softening stool w/ docusate, sitz baths, and pain control, which is effective but may be associated w/ longer time taken for symptom relief and a higher recurrence rate.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Fecal Incontinence (FI)</strong></summary>
            <div>
                <ul><li>Involuntary loss of solid or liquid feces.</li><li>Anal incontinence also includes involuntary loss of flatus.</li><li>Prevalence of FI in community increases w/ age and varies from 2.2% to 25%.</li></ul>
                
        <details>
            <summary><strong>FI Prevalence</strong></summary>
            <div>
                <ul><li>In community surveys, age-adjusted prevalence is ≈9% in US but lower in global surveys.</li><li>Prevalence rates related to frequency of FI that is required for case definition: in a survey of US, Canada, and England, overall prevalence of FI in last 3 months was 16%, but in only 2.1% of these cases did it occur twice a month and last at least 6 months.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Impact of FI</strong></summary>
            <div>
                <ul><li>Impacts daily quality of life and may predispose to institutionalization: up to 50% of nursing home residents in 1 survey had FI.</li><li>Only a small proportion of incontinent patients discuss symptom w/ a physician; physicians should ask patients w/ predisposing risk factors when they have FI.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Associated Factors</strong></summary>
            <div>
                <ul><li>Older age, diarrhea (frequent stools or loose stools), rectal urgency, constipation (infrequent stools, hard stools), and urinary incontinence are associated w/ FI.</li><li>Women are more likely than men to report FI, but differences are small (1%–2%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Obstetric Anal Sphincter Injury</strong></summary>
            <div>
                <ul><li>During childbirth may cause FI, although more typically, FI begins 2-3 decades after vaginal delivery.</li><li>Other medical disorders that cause changes in stool consistency and/or anorectal weakness also predispose to FI.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Specific Diseases</strong></summary>
            <div>
                <ul><li>Central nervous system (dementia and stroke), peripheral nervous system (diabetic peripheral neuropathy, spinal cord injury, and pelvic anomalies), and inflammatory bowel disease are associated w/ FI.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Assessment</strong></summary>
            <div>
                <ul><li>No biomarker for FI.</li><li>Multiple demographic, physiological, medical, and psychiatric comorbidities are strongly associated w/ FI, but there is no single factor that is always present in a patient w/ FI.</li><li>Higher number of risk factors present, greater likelihood that FI will occur.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Aims</strong></summary>
            <div>
                <ul><li>Aim of diagnostic assessment is to identify all factors that contribute to FI and to order them in terms of which ones are easiest to modify.</li><li>Risk factors interact so that treatment of 1 risk factor may lower overall prevalence of FI and restore continence.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Bristol Stool Form Scale</strong></summary>
            <div>
                <ul><li>Validated set of pictures of bowel movements.</li><li>Pictorial representations of stool form and bowel diaries are efficient and reliable methods to characterize bowel habits and are better predictors of colonic transit than self-reported stool frequency.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Bowel Diaries</strong></summary>
            <div>
                <ul><li>May provide additional information on stool frequency, although they are not standardized.</li><li>Specific questions about frequency, amount, type of leakage, and presence of urgency can be added to provide an index of symptom severity, which strongly correlates w/ impact of FI on quality of life and medical consultation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Urge vs. Passive Incontinence</strong></summary>
            <div>
                <ul><li>Patients w/ urge incontinence experience desire to defecate but cannot reach toilet in time; generally have reduced squeeze pressures, squeeze duration, or reduced rectal capacity w/ rectal hypersensitivity.</li><li>Patients w/ passive incontinence are not aware of need to defecate before incontinent episode; have lower resting pressures.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Incontinence During Sleep</strong></summary>
            <div>
                <ul><li>Uncommon; occurs in patients w/ diabetes mellitus, isolated internal anal sphincter weakness, or scleroderma.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Physical Examination</strong></summary>
            <div>
                <ul><li>Should exclude diseases in which FI is secondary.</li><li>Meticulous anorectal examination is mandatory in every patient w/ FI, not only to identify rectal masses but also to gauge anal sphincter tone and pelvic floor motion at rest, during voluntary contraction of anal sphincter and pelvic floor muscles, and during simulated evacuation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Perianal Sensation and Anal Wink Reflex</strong></summary>
            <div>
                <ul><li>Evaluate integrity of sacral lower motor neuron reflex arc.</li><li>For experienced observers, there is good agreement between digital assessment of anal sphincter function when at rest and during squeeze.</li><li>Other abnormalities in patients w/ FI include abnormal pelvic floor motion during evacuation, impacted stool in rectal vault, and perianal soiling w/ feces.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Test Tailoring</strong></summary>
            <div>
                <ul><li>Tests are tailored to patient’s age, probable etiological factors, symptom severity, impact on quality of life, response to conservative medical management, and availability of tests.</li><li>ARM, rectal BET, and rectal sensation should be performed in patients who fail to respond to conservative measures.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Anorectal Manometry (ARM)</strong></summary>
            <div>
                <ul><li>Anal sphincter resting and squeeze pressures are key parameters.</li><li>Because anal sphincter pressures decline w/ age and are lower in women, age and sex should be taken into consideration when interpreting anal canal pressure.</li><li>Anal cough reflex is also useful for evaluating integrity of lower motor neuron innervation of external anal sphincter.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Rectal Sensation in FI</strong></summary>
            <div>
                <ul><li>May be normal, increased, or decreased.</li><li>Rectal sensory and rectal evacuation dynamics may change w/ biofeedback therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Anal Imaging</strong></summary>
            <div>
                <ul><li>With endoanal ultrasound or MRI should be considered in patients w/ weak pressures especially if surgery is being considered.</li><li>Although findings of endoanal ultrasound and MRI are generally congruent, each of these modalities has unique strengths.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoanal Ultrasound vs. MRI</strong></summary>
            <div>
                <ul><li>Internal sphincter is visualized clearly by endoanal ultrasound, whereas MRI is superior for discriminating between an external anal sphincter tear or a scar and for identifying external sphincter atrophy.</li><li>Internal sphincter defects probably reflect more severe anorectal injury than do external sphincter injuries alone.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Anal Sphincter Injury Interpretation</strong></summary>
            <div>
                <ul><li>Challenging even for experienced radiologists.</li><li>Even asymptomatic women can have postpartum sphincter defects.</li><li>2D ultrasound identifies anal sphincter defects after vaginal delivery in up to one-third of women, but w/ 3D ultrasound or MRI, prevalence is ≈10%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Further Testing</strong></summary>
            <div>
                <ul><li>Assessment of rectal compliance and sensation w/ a barostat, needle EMG of anal sphincter, and assessment of pelvic floor motion by dynamic MRI or barium proctography may be considered for patients who have refractory symptoms, especially if surgery is being considered.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Needle EMG</strong></summary>
            <div>
                <ul><li>Should be considered in patients w/ clinically suspected neurogenic sphincter weakness, particularly if there are features suggestive of proximal (i.e., sacral root) involvement.</li><li>Although pudendal nerve terminal motor latency may be significantly prolonged in some patients w/ idiopathic FI, this test has low clinical significance ∵ its low reliability.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Treatment of Fecal Incontinence</strong></summary>
            <div>
                <ul><li>Impairs quality of life.</li><li>Most individuals have it less than once a month or it consists only of staining of underclothes.</li><li>Choices of therapy depend on severity of FI and presence of other comorbid conditions such as dementia that may moderate other treatments such as biofeedback.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conservative Treatment</strong></summary>
            <div>
                <ul><li>Relatively low in cost and has few adverse events.</li><li>Includes: (i) educating patient about diarrhea and constipation as causes of FI; (ii) use of drugs such as loperamide or diphenoxylate for diarrhea and fiber supplements and/or laxatives for constipation and (iii) daily pelvic floor exercises to strengthen pelvic floor muscles.</li><li>Bowel diary may be added to monitor progress.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conservative Treatment Efficacy</strong></summary>
            <div>
                <ul><li>Often inconsistently implemented.</li><li>When properly taught and followed up by a health care professional, up to 20% of patients may not need further treatment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Controlled Trial of FI Treatments</strong></summary>
            <div>
                <ul><li>171 patients w/ FI were randomly allocated to 4 groups: standard medical/nursing care (i.e., advice only), advice plus verbal instruction on sphincter exercises, hospital-based computer-assisted sphincter pressure biofeedback, or hospital biofeedback plus use of a home EMG biofeedback device.</li><li>Symptoms improved in 55% and resolved in 5% w/ no differences between treatment groups, and improvement was sustained at 1 year.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>FI with Diarrhea</strong></summary>
            <div>
                <ul><li>Several drugs to manage diarrhea (e.g., loperamide, diphenoxylate w/ atropine, bile salt binding agents such as cholestyramine and colesevelam, anticholinergic agents, and clonidine) are available.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cochrane Review of Diarrhea Drugs</strong></summary>
            <div>
                <ul><li>Identified 13 randomized studies w/ 473 participants.</li><li>Nine trials included only persons w/ FI related to liquid stool, and 7 tested antidiarrheal drugs (loperamide, diphenoxylate plus atropine, and codeine).</li><li>In 4 trials, symptoms were better w/ active treatment compared w/ placebo, w/ improved and/or restored fecal continence, improved fecal urgency, more formed stools, and reduced use of pads.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diet Education</strong></summary>
            <div>
                <ul><li>Advice on relationship between foods containing incompletely digested sugars (e.g., fructose and lactose) and caffeine for loose stools and urgency may also be helpful, but evidence is limited.</li><li>65% of 65 patients reported improved fecal continence on a low FODMAP diet in an uncontrolled, retrospective audit of patients seen in clinical practice.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>FI with Constipation</strong></summary>
            <div>
                <ul><li>Laxative regimens sometimes benefit children and older patients w/ FI associated w/ constipation, but benefits in younger adults are not supported by objective evidence.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Anorectal Biofeedback for FI</strong></summary>
            <div>
                <ul><li>Also appropriate for FI, but w/ minor differences in focus.</li><li>FI often accompanied by diarrhea and constipation and weakness of external anal sphincter.</li><li>Biofeedback therapy for FI seeks to increase strength and coordination of external anal sphincter w/o contracting abdominal wall muscles and to improve rectal sensation where necessary.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biofeedback for Hypersensitivity</strong></summary>
            <div>
                <ul><li>In those patients w/ hypersensitivity to rectal distention who cannot delay defecation, biofeedback seeks to reduce rectal sensation so that patients can postpone defecation until more stool fills rectum.</li><li>Biofeedback for FI should be tailored to symptoms and specific anorectal dysfunctions.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations to Biofeedback Training</strong></summary>
            <div>
                <ul><li>Much less effective in patients who have short-term memory loss related to dementia or depression.</li><li>Requires a motivated patient and reinforcement over time.</li><li>Patients w/ central nervous system etiologies for their FI such as spinal cord injury or head injury may be less amenable to biofeedback training.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biofeedback Efficacy Studies</strong></summary>
            <div>
                <ul><li>In a controlled study, biofeedback therapy was more effective than attention control therapy; both groups were also treated w/ other conservative approaches.</li><li>However, biofeedback therapy was not superior to conservative measures or pelvic floor exercises alone or to education.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biofeedback Plus Loperamide</strong></summary>
            <div>
                <ul><li>Was not more effective than biofeedback plus placebo.</li><li>One possible explanation is that patients in these trials were not initially treated w/ other conservative measures for FI before they received biofeedback therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Biofeedback Benefits</strong></summary>
            <div>
                <ul><li>Among patients who did not adequately respond to medications, education, and behavioral therapy, 76% of patients treated w/ treated w/ biofeedback versus 41% w/ pelvic floor exercises alone reported adequate relief at 3 months.</li><li>Biofeedback therapy benefits many patients and does not cause harm; regarded by many as a mainstay of treatment for FI.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Anal Plugs</strong></summary>
            <div>
                <ul><li>Mechanical barrier devices.</li><li>Renew is a silicone anal insert that is disposable.</li><li>In 1 study of 30 patients w/ FI, 20% disliked device, 23% showed no change, and 12% reported worse symptoms of FI; however, 57% of patients wished to continue using device.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Renew Device in Anileoanal Pouch</strong></summary>
            <div>
                <ul><li>In a second study, Renew device was used in 15 patients w/ anileoanal pouch: 8 of 15 (53%) found Renew device to be acceptable, and 6 of 15 (40%) reported it to be effective.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Peristeen Anal Plug</strong></summary>
            <div>
                <ul><li>Available in Europe.</li><li>One review concluded that plugs are difficult to tolerate but may be useful in a select group of patients and may be used as an adjunct to other treatments.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Eclipse Vaginal Bowel Control Device</strong></summary>
            <div>
                <ul><li>Balloon that is inserted into vagina and acts as a mechanical barrier, compressing anterior wall of rectum.</li><li>Correct-sized balloon has to be selected for each patient, and manual dexterity is required to deflate, inflate, insert, and remove device.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Eclipse Device Studies</strong></summary>
            <div>
                <ul><li>In first series, 61 patients were evaluated for 1 month.</li><li>A 50% reduction in FI was reported by 86%, and quality of life improved.</li><li>Adverse events such as cramping and abdominal pain were reported during fitting period.</li><li>Another study showed reductions in urgency, frequency, and incomplete evacuations in more than 50% of patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Perianal Cotton Plugs</strong></summary>
            <div>
                <ul><li>Patients w/ passive incontinence for small amounts of stool may benefit from perianal cotton plugs to absorb moisture and to reduce uncontrolled passage of gas.</li><li>However, there are no formal studies w/ this intervention.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Injectable Bulking Agents</strong></summary>
            <div>
                <ul><li>Used to augment urethral sphincter and treat urinary incontinence, were approved by US Food and Drug Administration for managing FI.</li><li>In a multicenter, placebo-controlled randomized trial of a perianal bulking agent (dextranomer in stabilized hyaluronic acid [NASHA Dx]) in 206 patients w/ FI, a ≥50% reduction in incontinence episodes was reported more frequently for NASHA Dx (52% patients) than placebo (31% patients).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>NASHA Dx Adverse Events</strong></summary>
            <div>
                <ul><li>Two serious adverse events occurred (i.e., rectal abscess and prostatic abscess), but most adverse events were minor.</li><li>Treatment did not affect embarrassment scores related to FI.</li><li>Anorectal physiological tests and imaging were not performed; hence, patient characteristics and mechanisms of action were unknown.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>NASHA Dx Long-Term Study</strong></summary>
            <div>
                <ul><li>A prospective multicenter trial in 136 FI patients found that fecal continence improved in 52% of patients in 6 months, and this was sustained after 36 months.</li><li>Further studies to compare effects of bulking agents to biofeedback therapy in FI are ongoing.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Radiofrequency Stimulation (SECCA Procedure)</strong></summary>
            <div>
                <ul><li>Involves radiofrequency stimulation of muscles in anal canal to increase muscle connective tissue ratio and scarring via a probe w/ needles in anal canal performed under local anesthesia and sedation.</li><li>Despite initial positive studies including a multi-center trial from 2003, more recent reports suggest poor long-term results.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sacral Nerve Electrical Stimulation (SNS)</strong></summary>
            <div>
                <ul><li>Approved for treating FI in Europe and US.</li><li>Patients whose symptoms respond to temporary SNS for 2–3 weeks have device implanted in their abdomen.</li><li>Between 2002 and 2008, pivotal North American multicenter controlled study enrolled 133 patients w/ FI characterized as having &gt;2 incontinent episodes per week for &gt;6 months or for &gt;12 months after childbirth and who had failed or were not candidates for conservative therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>SNS Exclusion Criteria</strong></summary>
            <div>
                <ul><li>Patients w/ chronic diarrhea, large sphincter defects, chronic inflammatory bowel disease, visible sequelae of pelvic radiation, active anal inflammation, and neurologic diseases such as clinically significant peripheral neuropathy or complete spinal cord injury were excluded.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>SNS Success Rates</strong></summary>
            <div>
                <ul><li>Success rate for temporary SNS was 90%.</li><li>At follow-up 3 years later, 86% of those w/ an implanted device achieved a ≥50% reduction in number of incontinent episodes per week (therapeutic success), and 40% achieved complete continence.</li><li>Incontinent episodes decreased from a mean of 9.4 per week at baseline to 1.7 at 12 months.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>SNS Adverse Events</strong></summary>
            <div>
                <ul><li>Most common device-related adverse events were implant site pain (28%), paresthesias (15%), change in sensation of stimulation (12%), and infection (10%).</li><li>Despite marked improvement in symptoms in this uncontrolled study, SNS has had no significant effects on measured anorectal functions.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Less Invasive Methods</strong></summary>
            <div>
                <ul><li>Percutaneous tibial nerve stimulation (PTNS) and transcutaneous tibial nerve stimulation (TTNS).</li><li>PTNS stimulates tibial nerve through a needle inserted above ankle of 1 leg, and TTNS stimulates between pads attached to sole of 1 foot.</li><li>Both approaches reduced frequency of FI in uncontrolled case series.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PTNS vs. TTNS</strong></summary>
            <div>
                <ul><li>Small study comparing PTNS w/ TTNS and sham stimulation showed PTNS to be more effective than TTNS or sham (82%, 48%, and 13% for reducing frequency of FI by at least 50%; P = 0.035).</li><li>In contrast, a large multicenter European study compared 12 weekly sessions of PTNS to sham stimulation.</li><li>Outcomes at end of treatment showed no significant difference between 2 techniques (38% for PTNS and 31% for sham).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Anal Sphincteroplasty</strong></summary>
            <div>
                <ul><li>Surgical repair of a separated internal and/or external anal sphincter.</li><li>Separated end of sphincter are brought together or overlapped and sutured together for healing.</li><li>Although short-term improvements in FI occur in up to 85% of patients, continence deteriorates thereafter and averages 50% after 40–60 months.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Sphincteroplasty Recommendation</strong></summary>
            <div>
                <ul><li>Recommended for patients in whom FI and anal sphincter injury are recognized shortly after vaginal delivery or other injury, w/ symptoms persisting despite adequate therapy of coexisting bowel disturbances.</li><li>May also be reserved when medical, noninvasive therapies and SNS have failed or a device is not recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Dynamic Graciloplasty</strong></summary>
            <div>
                <ul><li>Involved bringing a segment of gracilis muscle up to anal canal to wrap around anal sphincter, often w/ electrical stimulation.</li><li>Significant associated morbidity and even mortality w/ only modest benefits; procedure is not currently recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Miscellaneous Devices</strong></summary>
            <div>
                <ul><li>Numerous attempts have been made to artificially enhance anal sphincter to improve continence.</li><li>Most of these devices have shown unacceptable complication rates or explant rates and are not currently available.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Colostomy or Ileostomy with an End Stoma</strong></summary>
            <div>
                <ul><li>Considered a last resort in algorithm of treatment for FI.</li><li>During evaluation and management of patients w/ severe FI, this option should be discussed early so that patients are aware of same.</li><li>Even in very frail patients, post-procedure morbidity is low.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>End Stoma Quality of Life</strong></summary>
            <div>
                <ul><li>May markedly improve quality of life.</li><li>In 1 study, median score (scale of 0–10) for ability to live w/ a stoma was 8, and satisfaction w/ stoma was rated as a median of 9.</li><li>Most (83%) felt that stoma restricted their life a little or not at all, which was significantly improved from perceived former restriction due to incontinence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
